One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Replimune Group REPL just hit that ...

When it comes to short-term investing or trading, they say "the trend is your friend." And there's no denying that this is the most profitable strategy. But making sure of the sustainability of a ...

Investors are always looking for stocks that are poised to beat at earnings season and Replimune REPL may be one such company. The firm has earnings coming up pretty soon, and events are shaping up ...

Thursday, Replimune Group Inc (NASDAQ:REPL) released topline results from the primary analysis of the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma. Bristol-Myers Squibb Co’s ...

The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $12.82 / share. This is an increase ...

RP1 combination therapy showed improvements but did not meet either of the two primary endpoints. Portfolio reprioritization extends cash runway to early 2026. Find out which stock just claimed the ...